Alimta may be pulled from use in Britain because of expense

Some controversey in the UK and a little tension between the medical establishments in Scotland and England. The Scottish Medicines Consortium approved alimta for mesothelioma treatment last year, but now the UK’s National Institute for Health and Clinical Excellence, based in England, is saying the drug is too expensive. According to this article, “It is the first time a ruling by NICE has been at odds with a decision by the Scottish Medicines Consortium and campaigners are calling on health officials north of the border to stand by their decision.”

Activists in Scotland are upset.